EGFR and non-small cell lung carcinoma: There is evidence that KRAS mutations are highly specific negative prognostic factors of response (de novo resistance) to EGFR-targeted therapy in both NSCLC and colorectal cancer (Bokemeyer et al, 2009; Jackman et al, 2009).